Urologix, Inc.
ULGX
$0.00
-$0.01-99.21%
OTC PK
| 03/31/2015 | 12/31/2014 | ||||
|---|---|---|---|---|---|
| Revenue | -9.20% | 1.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.20% | 1.95% | |||
| Cost of Revenue | -8.05% | 3.59% | |||
| Gross Profit | -10.52% | 0.14% | |||
| SG&A Expenses | -7.53% | -7.86% | |||
| Depreciation & Amortization | -5.88% | -26.09% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.21% | -1.52% | |||
| Operating Income | -14.18% | 44.40% | |||
| Income Before Tax | 1.13% | 18.29% | |||
| Income Tax Expenses | -- | -20.00% | |||
| Earnings from Continuing Operations | 2.24% | 18.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.24% | 18.31% | |||
| EBIT | -14.18% | 44.40% | |||
| EBITDA | -133.33% | 83.18% | |||
| EPS Basic | 2.44% | 19.21% | |||
| Normalized Basic EPS | 0.99% | 19.84% | |||
| EPS Diluted | 0.00% | 1.48% | |||
| Normalized Diluted EPS | 0.99% | 19.84% | |||
| Average Basic Shares Outstanding | 0.26% | 1.37% | |||
| Average Diluted Shares Outstanding | 0.26% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||